Abstract：Objective: To investigate the clinical effect of carthamin yellow body wall injection for myofascial pain syndrome, and to observe the safety of the drug. Methods: 80 patients with myofascial pain syndrome diagnosed in our hospital from July 2016 to June 2017 were selected. The data of 80 patients were analyzed. They were randomly divided into the control group and the observation group, 40 cases in each group. The observation group was given carthamin yellow which use body wall injection, while the control group was treated with dexamethasone sodium phosphate injection. The improvement of clinical symptoms in the two groups was compared with the visual analogue scale (VAS) to evaluate the degree of pain in the two groups of patients after 2, 4, 6 and 8 weeks, and the clinical results were compared before and after treatment in the group. Results: The ratio of clinical symptoms improvement in the observation group (82.5%) was significantly higher than that in the control group (67.5%). There was no significant difference in the VAS scores between the two groups before and after treatment (P>0.05). After 2, 4, 6 and 8 weeks of treatment, the VAS score of the observation group was significantly lower than that of the control group (P<0.05). There was no significant difference in blood routine, liver and kidney function before treatment and after treatment in the observation group (P>0.05). Conclusion: The clinical application of carthamin yellow body wall injection can obviously reduce the pain degree of the patients, and the curative effect is stable. The quality of life of patients is greatly improved, and almost of the patients have no obvious side effects, and the drug safety is worth widely popularizing in clinical practice.
2018, Vol. 24 
冀公网安备13080202000677号